# Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

> **NCT01312961** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 104 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo (for Dupilumab)
- **DRUG:** Fluticasone/Salmeterol combination therapy
- **DRUG:** Fluticasone monotherapy
- **DRUG:** Albuterol
- **DRUG:** Levalbuterol

## Key facts

- **NCT ID:** NCT01312961
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01312961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01312961, "Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01312961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*